HOBSCOTCH-YOUTH and Young Adults

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age13-29
SponsorDartmouth-Hitchcock Medical Center

About this trial

The goal of this clinical trial is to learn more about the home-based epilepsy self-management program, HOBSCOTCH, for improving cognitive function (thinking and memory) and quality of life specifically in young adults, ages 18 - 29 years, who have epilepsy. It will also learn if a modification of the program for youth with epilepsy, ages 13 - 17, improves thinking and memory and quality of life and reduces stress for their parents.

Researchers will enroll 260 young adults with epilepsy and 40 youth with epilepsy and their parent or guardian. Researchers will compare responses to questionnaires and surveys before and after participation in the HOBSCOTCH program to see if thinking, memory and quality of life have improved for young adults and youth with epilepsy and to see if parents have improved quality of life as well.

Participants will:

* Attend 9 weekly one-hour sessions of the HOBSCOTH program in their homes with a one-on-one coach using their computer or their phone; youth with epilepsy (ages 13 - 17) will attend alongside a parent or legal guardian. * Keep a short daily diary about their seizures and activity in the program using a smart phone app(lication) * Complete surveys and questionnaires before HOBSCOTCH and 3 months and 6 months later.

There are no study visits to a medical center. HOBSCOTCH is a virtual or telehealth intervention.

Eligibility criteria

Qualifiers

Age 18 - 29 years for YAWE

Age 13 - 17 years for YWE

For YWE at least one parent or legal guardian provides consent and agrees to participate

Diagnosis of epilepsy (controlled or uncontrolled seizures)

Disqualifiers

Active psychosis (any participant)

Illicit substance abuse (any participant)

Severe cognitive/intellectual disability (any participant)

YWE cannot participate without a parent and parent's consent (or legal guardian)

Trial design

Treatments tested in this trial

  • HOBSCOTCH/HOBSCOTCH-YOUTH

Treatment groups

300 Participants
are divided into 1 treatment group

Sponsors and collaborators

Dartmouth-Hitchcock Medical Center

Lead sponsor

Epilepsy Wellness Advocates

Collaborator